Stock Titan Trading tools for traders and investors.

-

04:47:47 PM

Last OCGN Stock Market News

OCGN - Ocugen Inc

03/08/21 2:50 PM

Nasdaq : OCGN

Ocugen Inc. to Present at Upcoming March Investor Conferences

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will present at

RHEA-AI

neutral

03/03/21 8:00 AM

Nasdaq : OCGN

Ocugen's COVID-19 Vaccine Co-Development Partner, Bharat Biotech shares Phase 3 Interim Results of COVAXIN, Demonstrates Efficacy of 81%

Data from 25,800 participants in Phase 3 trial in India, received vaccine or placebo in a 1:1 ratio showed that the vaccine candidate was well tolerated and demonstrated 81% efficacy in preventing COVID-19 in those without prior infection after the second dose. Clinical trial to continue through to

RHEA-AI

negative

02/23/21 7:30 AM

Nasdaq : OCGN

European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis Pigmentosa and Leber Congenital Amaurosis

Ocugen, Inc., (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that on the

RHEA-AI

neutral

02/10/21 9:00 PM

Nasdaq : OCGN

Ocugen, Inc. Announces Closing of $23 Million Registered Direct Offering of Common Stock

Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that it has closed the previously

RHEA-AI

neutral

02/07/21 9:44 PM

Nasdaq : OCGN

Ocugen Inc. Announces $23 Million Registered Direct Offering of Common Stock Priced at a Premium to Market

Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that it has entered into

RHEA-AI

neutral

01/12/21 7:52 AM

Nasdaq : OCGN

Ocugen Inc. Announces the Cancellation of Stockholder Meeting Previously Adjourned to 11:00 a.m. Eastern Time on January 13, 2021

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced it has determined to withdraw from

RHEA-AI

neutral

01/08/21 3:17 PM

Nasdaq : OCGN

Ocugen Inc. Regains Compliance with Nasdaq Bid Price Rule

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today received formal notification from The Nasdaq

RHEA-AI

neutral

01/08/21 8:00 AM

Nasdaq : OCGN

Ocugen Inc. to Present at CTIC, HC Wainwright and Noble Capital Investor Conferences

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and develop a vaccine to fight COVID-19, today announced that it will present at the 2021 CTIC

RHEA-AI

neutral

12/23/20 7:15 PM

Nasdaq : OCGN

Ocugen Establishes Vaccine Scientific Advisory Board

Ocugen, Inc., (NASDAQ: OCGN), a leading biopharmaceutical company focused on discovering, developing

RHEA-AI

neutral

12/22/20 9:07 PM

Nasdaq : OCGN

Ocugen Inc. Announces Plan to Adjourn Annual Meeting of Stockholders, Modify Proposal Regarding Increase in Number of Authorized Shares

RHEA-AI

neutral